Member Info for Newuncle

CiRT

The potential benefits from CiRT include:

FIRST OF IT'S KIND

The EpiSwitch CiRT is a first-of-its-kind blood test that accurately predicts an individual cancer patient's therapeutic response to immune checkpoint inhibitors (ICIs), providing unique benefits for physicians in treatment planning and navigating complex decisions [1,2].

STATE OF THE ART PERSONALISED GUIDANCE

ICIs offer a real hope of durable disease control for some patients. Despite pre-screening with current standard tests such as tumor PD-L1 expression, these costly ICIs offer a long-term survival advantage to less than 1 in 4 patients [3], and many may become seriously ill and require hospital admission. Under this new agreement between Bupa and OBD, Bupa health insurance customers who are being considered for immunotherapy with an anti-PD-1/L1 ICI will be offered the CiRT test, ensuring their doctor receives state-of-the-art personalized guidance to inform their treatment plan.

SPARING PATIENTS FROM SIDE EFFECTS OF INEFFECTIVE ICI TREATMENTS

The partnership underscores the shared vision of Bupa and OBD to improve the quality of patient care, while sparing many individuals from unwarranted side effects from ICI treatments that are ineffective for them.

Far too much ramping here, I mean look at this ridiculous statement, why is no one listening to jadams excellent advice?

Oxford BioDynamics @OxBioDynamics

We’re thrilled to announce our partnership with the UK’s leading health insurance company

@BupaUK to enhance access to @EpiSwitchCiRT in the UK: https://obdx.co/o0a.

Bupa UK health insurance customers being considered for immune checkpoint inhibitors (ICIs) for #cancer treatment will now be offered our CiRT test to accurately predict their response, providing unique benefits for physicians in treatment planning and navigating complex decisions.

The partnership underscores the shared vision of Bupa and OBD to improve the quality of patient care while sparing many individuals from unwarranted side effects from ICI treatments that are ineffective for them.

I'm disappointed not to see more sellers, instead we have buyers ignoring the excellent advice from jadams, what on earth are they doing?

01234 thanks very much.

Now where are those sellers?

Yup they only raised £6m for that in the summer so placing coming?

Jadams thanks so is obd a buy, hold or sell in your opinion?

Tricky totally on the same page as you on all comments. Great you keep us informed doing a great job.

Exactly tricky we are posting so others dont fall for the short term moves.

Tricky yup. So now obd have been green lighted by USA medical insurance providers for PSA tests and by Bupa for cirt tests. But like being given open cheque books by your buyers eh?

Tricky so true

I will buy more of these but not until the latest round of games with SP have been fully played out, whenever that is.

Tricky,

I know what I am seeing and so do you. End of, not getting into a row about this with 404, life's too short.

No I was asking you to back up your views.

Anyway I found this fwiw, clear as mud

https://www.proactiveinvestors.co.uk/companies/news/81/idiots-guide-to-the-london-stock-exchanges-setsmm-0379.html

404 can you show us exactly how that works then.....we need educating it seems....prove your statement of fact with proof

Current Bid 35.5 Offer 36.90

Yesterday Close Bid 31.6 Offer 32.9

So we now have a difference of just 4p following that RNS.....absolute joke

Tricky,

Wrong but its effective if you want to shake the tree for someone else's benefit I guess.

tricky,

they are really taking **** now

This bit clearly shows why CiRT is urgently needed:

Approximately two thirds of patients treated with checkpoint inhibitors (PD-1/PD-L1 and/or CTLA-4) experience little or no benefit exposing patients to the unacceptable risk of potentially severe immune related side effects (irAEs) such as pneumonitis and gastritis.

Now that's really worth addressing is it not?

IMO Real movement will follow sustained gains instead of morning run ups being quickly followed by afternoon selling down, the pattern has been established so it becomes the "norm" regardless of the actual news, especially if the news is not about a valuable contract with £s values stated. It will come and the games will end.

Broker Update Part 3

Awareness of EpiSwitch cancer franchise growing: Much of the recent interest in EpiSwitch has been driven by the recent launch of the company’s prostate cancer (PSE) test. PSE is targeting a considerably larger market opportunity than CiRT with 25m PSA tests conducted per year in the US alone. Our expectation is that success with the PSE test should also help boost OBD’s overall cancer franchise raising awareness also of the CiRT test. In the longer term we look forward to the availability of additional cancer tests with colorectal cancer previously highlighted, to flesh out the company’s cancer credentials. House Stock.